Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Apr
16
2024
This Week in 340B: April 9 – April 15, 2024 McDermott Will & Emery
Jun
12
2017
FDA Extends Unique Device Identification (UDI) System Compliance Deadlines for Certain Low-Risk Medical Devices McDermott Will & Emery
Jun
20
2017
Supreme Court Analyzes Key Provisions of Biologics Price Competition and Innovation Act of 2009 McDermott Will & Emery
Mar
10
2021
CDC Releases Initial Guidance: Fully Vaccinated People Can Visit Others, May Not Have to Quarantine After COVID-19 Exposure McDermott Will & Emery
Mar
31
2021
340B in 2021: What Covered Entities and Their Partners Need to Know Now Recap McDermott Will & Emery
Dec
19
2011
Treasury Clarifies 5 Percent Safe Harbor Ownership Guidelines for Section 1603 Grants for Renewable Energy Projects McDermott Will & Emery
Mar
23
2018
TTB Publishes Additional Tax Act Guidance on 5010 Wine and Flavor Credits McDermott Will & Emery
Apr
28
2013
Internal Revenue Service ("IRS") Updates Notice Determining When Construction Begins for Purposes of the Production Tax Credit and Investment Tax Credit McDermott Will & Emery
May
16
2013
Base-Erosion and Profit-Shifting – Organization for Economic Co-operation and Development (OECD) Report McDermott Will & Emery
Jun
17
2013
Massachusetts Department of Energy Resources (DOER) Unveils Emergency Regulation to Address Oversupply of Solar Applications McDermott Will & Emery
Jun
30
2013
No Anti-Suit Injunction Where Foreign Arbitration Controls Resolution of Licensing Dispute McDermott Will & Emery
Jun
17
2021
Paris Court of Appeals Rejects Pharmaceutical Supplementary Protection Certificate Applications McDermott Will & Emery
Jun
25
2021
McDermottPlus Check-Up: June 25, 2021 Infrastructure, Cost Sharing & Vaccination Goal McDermott Will & Emery
Nov
7
2013
The President’s New Climate Change Executive Order – What Does it Mean for the Energy Sector? McDermott Will & Emery
Oct
8
2018
New CBMA Guidance Further Clarifies Excise Tax Rules for Imported Beverages McDermott Will & Emery
Oct
19
2018
Further CBP Guidance on Craft Beverage Modernization Act McDermott Will & Emery
Oct
15
2021
McDermottPlus Check-Up: October 15, 2021 McDermott Will & Emery
Nov
13
2018
CFIUS Broadens Coverage of Cross-Border Biotech Transactions McDermott Will & Emery
Nov
30
2018
7th Circuit Issues Lebamoff Opinion McDermott Will & Emery
Dec
10
2021
McDermottPlus Check-Up: December 10, 2021 McDermott Will & Emery
Jan
8
2019
FDA 2018 Year in Review: Advertising and Promotion McDermott Will & Emery
Jan
14
2019
Congressional Cannabis Caucus – 116th Congress McDermott Will & Emery
Jun
2
2014
Federal Court Vacates 340B Rule Regarding Orphan Drugs McDermott Will & Emery
Feb
7
2019
2018 Digital Health Year in Review: Focus on Care Coordination and Reimbursement McDermott Will & Emery
Feb
22
2019
Annual EU Competition Review 2018 McDermott Will & Emery
Sep
26
2014
Merck Boosts Life Sciences Industry with Sigma-Aldrich Acquisition McDermott Will & Emery
Apr
15
2022
Revised CDC Guidance for Prescribing Opioids Emphasizes Physician Judgment, Reflects Concerns About Misapplication of Earlier Guidance McDermott Will & Emery
Oct
28
2014
CMS Releases Preliminary 2015 Clinical Laboratory Fee Schedule Rates McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins